Finally, as there are similarities in the pathogenesis of EC with eosinophilic esophagitis (EoE), biologic medications undergoing clinical trials for the treatment of EoE are potential therapeutic agents for EC (Anti-IL5, anti-IgE monoclonal antibodies, anti-tumor necrosis factor (TNF-α) [4]. The gene discussed is IL5; the disease is eosinophilic esophagitis.